Does the media refer more to PACB or CYRX?

In the previous week, CryoPort had 6 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 8 mentions for CryoPort and 2 mentions for Pacific Biosciences of California. CryoPort's average media sentiment score of 0.81 beat Pacific Biosciences of California's score of 0.68 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacific Biosciences of California 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CryoPort 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, PACB or EVO?

Evotec has higher revenue and earnings than Pacific Biosciences of California. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pacific Biosciences of California $159.27M 2.24 -$546.38M -$0.43 N/A Evotec $717.28M 0.97 -$117.12M N/A N/A

Does the media refer more to PACB or EVO?

In the previous week, Evotec had 14 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 16 mentions for Evotec and 2 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 0.68 beat Evotec's score of -0.18 indicating that Pacific Biosciences of California is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacific Biosciences of California 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral

Pacific Biosciences of California (PACB) Competitors

$1.15 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.16 +0.01 (+0.87%)

As of 08/14/2026 07:34 PM Eastern

Compare

PACB vs. TXG, CYRX, EVO, MLAB, and CTKB

Should you buy Pacific Biosciences of California stock or one of its competitors? Pacific Biosciences of California's main competitors and comparable companies include 10x Genomics (TXG), CryoPort (CYRX), Evotec (EVO), Mesa Laboratories (MLAB), and Cytek Biosciences (CTKB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Pacific Biosciences of California compare to 10x Genomics?

10x Genomics (NASDAQ:TXG) and Pacific Biosciences of California (NASDAQ:PACB) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

10x Genomics has a net margin of -12.18% compared to Pacific Biosciences of California's net margin of -82.49%. 10x Genomics' return on equity of -9.33% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-12.18%	-9.33%	-7.30%
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%

10x Genomics has a beta of 2.03, suggesting that its share price is 103% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market.

10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$616.91M	11.54	-$43.54M	-$0.59	N/A
Pacific Biosciences of California	$159.27M	2.24	-$546.38M	-$0.43	N/A

10x Genomics presently has a consensus price target of $38.31, indicating a potential downside of 31.70%. Pacific Biosciences of California has a consensus price target of $1.83, indicating a potential upside of 59.42%. Given Pacific Biosciences of California's higher possible upside, analysts plainly believe Pacific Biosciences of California is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.25
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

84.7% of 10x Genomics shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, 10x Genomics had 11 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 13 mentions for 10x Genomics and 2 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 0.68 beat 10x Genomics' score of 0.44 indicating that Pacific Biosciences of California is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	3 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacific Biosciences of California	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

10x Genomics beats Pacific Biosciences of California on 11 of the 16 factors compared between the two stocks.

How does Pacific Biosciences of California compare to CryoPort?

Pacific Biosciences of California (NASDAQ:PACB) and CryoPort (NASDAQ:CYRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

CryoPort has a net margin of -20.05% compared to Pacific Biosciences of California's net margin of -82.49%. CryoPort's return on equity of -7.20% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%
CryoPort	-20.05%	-7.20%	-4.30%

Pacific Biosciences of California presently has a consensus target price of $1.83, suggesting a potential upside of 59.42%. CryoPort has a consensus target price of $18.00, suggesting a potential upside of 18.03%. Given Pacific Biosciences of California's higher possible upside, equities research analysts plainly believe Pacific Biosciences of California is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

92.9% of CryoPort shares are held by institutional investors. 3.7% of Pacific Biosciences of California shares are held by company insiders. Comparatively, 9.5% of CryoPort shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

CryoPort has higher revenue and earnings than Pacific Biosciences of California. CryoPort is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$159.27M	2.24	-$546.38M	-$0.43	N/A
CryoPort	$176.18M	4.38	$78.30M	-$0.90	N/A

In the previous week, CryoPort had 6 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 8 mentions for CryoPort and 2 mentions for Pacific Biosciences of California. CryoPort's average media sentiment score of 0.81 beat Pacific Biosciences of California's score of 0.68 indicating that CryoPort is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CryoPort	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacific Biosciences of California has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market.

Summary

CryoPort beats Pacific Biosciences of California on 12 of the 16 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Evotec?

Pacific Biosciences of California (NASDAQ:PACB) and Evotec (NASDAQ:EVO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

Evotec has higher revenue and earnings than Pacific Biosciences of California.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$159.27M	2.24	-$546.38M	-$0.43	N/A
Evotec	$717.28M	0.97	-$117.12M	N/A	N/A

5.8% of Evotec shares are held by institutional investors. 3.7% of Pacific Biosciences of California shares are held by insiders. Comparatively, 1.0% of Evotec shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pacific Biosciences of California currently has a consensus target price of $1.83, suggesting a potential upside of 59.42%. Evotec has a consensus target price of $3.00, suggesting a potential upside of 53.06%. Given Pacific Biosciences of California's higher probable upside, research analysts clearly believe Pacific Biosciences of California is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Evotec	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Evotec had 14 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 16 mentions for Evotec and 2 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 0.68 beat Evotec's score of -0.18 indicating that Pacific Biosciences of California is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Evotec has a net margin of -26.20% compared to Pacific Biosciences of California's net margin of -82.49%. Evotec's return on equity of -24.93% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%
Evotec	-26.20%	-24.93%	-11.35%

Pacific Biosciences of California has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market. Comparatively, Evotec has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market.

Summary

Evotec beats Pacific Biosciences of California on 9 of the 14 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Mesa Laboratories?

Pacific Biosciences of California (NASDAQ:PACB) and Mesa Laboratories (NASDAQ:MLAB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Mesa Laboratories has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$159.27M	2.24	-$546.38M	-$0.43	N/A
Mesa Laboratories	$249.13M	2.38	$6.71M	$0.84	126.24

Mesa Laboratories has a net margin of 1.92% compared to Pacific Biosciences of California's net margin of -82.49%. Mesa Laboratories' return on equity of 22.72% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%
Mesa Laboratories	1.92%	22.72%	9.82%

90.6% of Mesa Laboratories shares are held by institutional investors. 3.7% of Pacific Biosciences of California shares are held by insiders. Comparatively, 2.8% of Mesa Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Pacific Biosciences of California currently has a consensus price target of $1.83, suggesting a potential upside of 59.42%. Mesa Laboratories has a consensus price target of $110.00, suggesting a potential upside of 3.73%. Given Pacific Biosciences of California's higher probable upside, equities research analysts plainly believe Pacific Biosciences of California is more favorable than Mesa Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Mesa Laboratories	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pacific Biosciences of California has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market. Comparatively, Mesa Laboratories has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

In the previous week, Mesa Laboratories had 14 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 16 mentions for Mesa Laboratories and 2 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 0.68 beat Mesa Laboratories' score of 0.54 indicating that Pacific Biosciences of California is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesa Laboratories	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mesa Laboratories beats Pacific Biosciences of California on 11 of the 16 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Cytek Biosciences?

Pacific Biosciences of California (NASDAQ:PACB) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

69.5% of Cytek Biosciences shares are owned by institutional investors. 3.7% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cytek Biosciences has a net margin of -38.98% compared to Pacific Biosciences of California's net margin of -82.49%. Cytek Biosciences' return on equity of -12.40% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%
Cytek Biosciences	-38.98%	-12.40%	-9.17%

Pacific Biosciences of California currently has a consensus target price of $1.83, suggesting a potential upside of 59.42%. Cytek Biosciences has a consensus target price of $5.56, suggesting a potential upside of 18.60%. Given Pacific Biosciences of California's higher possible upside, analysts plainly believe Pacific Biosciences of California is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cytek Biosciences has higher revenue and earnings than Pacific Biosciences of California. Cytek Biosciences is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$159.27M	2.24	-$546.38M	-$0.43	N/A
Cytek Biosciences	$201.49M	3.03	-$66.54M	-$0.62	N/A

Pacific Biosciences of California has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market.

In the previous week, Cytek Biosciences had 2 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 4 mentions for Cytek Biosciences and 2 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 0.68 beat Cytek Biosciences' score of 0.47 indicating that Pacific Biosciences of California is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytek Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cytek Biosciences beats Pacific Biosciences of California on 11 of the 16 factors compared between the two stocks.

Get Pacific Biosciences of California News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PACB vs. The Competition

Export

Metric	Pacific Biosciences of California	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$357.46M	$9.64B	$7.02B	$13.06B
Dividend Yield	N/A	1.46%	2.57%	10.45%
P/E Ratio	-2.67	60.31	271.27	25.33
Price / Sales	2.24	262.17	583.79	76.92
Price / Cash	1.46	26.25	70.48	50.90
Price / Book	-10.45	37.50	12.92	6.25
Net Income	-$546.38M	$56.66B	$3.45B	$347.82M
7 Day Performance	-2.95%	0.26%	1.15%	1.08%
1 Month Performance	-24.84%	1.35%	1.37%	0.82%
1 Year Performance	-12.21%	17.32%	62.53%	20.99%

Pacific Biosciences of California Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PACB Pacific Biosciences of California	1.5443 of 5 stars	$1.15 flat	$1.83 +59.4%	-6.5%	$357.46M	$159.27M	N/A	730	Analyst Upgrade
TXG 10x Genomics	1.6862 of 5 stars	$58.57 +12.6%	$36.08 -38.4%	+323.6%	$6.61B	$642.82M	N/A	1,240	News Coverage Analyst Forecast Insider Trade
CYRX CryoPort	3.2297 of 5 stars	$14.82 -2.0%	$18.00 +21.5%	+72.3%	$765.81M	$176.18M	N/A	1,186	Insider Trade
EVO Evotec	2.9053 of 5 stars	$2.08 +4.0%	$3.00 +44.2%	-48.7%	$711.51M	$891.97M	N/A	4,553	News Coverage Short Interest Increase Analyst Revision Gap Down
MLAB Mesa Laboratories	1.2871 of 5 stars	$101.62 -1.0%	$94.00 -7.5%	+56.2%	$574.42M	$249.13M	84.68	680	News Coverage Earnings Report Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PACB) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pacific Biosciences of California (PACB) Competitors

PACB vs. TXG, CYRX, EVO, MLAB, and CTKB

How does Pacific Biosciences of California compare to 10x Genomics?

Summary

How does Pacific Biosciences of California compare to CryoPort?

Summary

How does Pacific Biosciences of California compare to Evotec?

Summary

How does Pacific Biosciences of California compare to Mesa Laboratories?

Summary

How does Pacific Biosciences of California compare to Cytek Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB vs. The Competition

Pacific Biosciences of California Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pacific Biosciences of California (PACB) Competitors

PACB vs. TXG, CYRX, EVO, MLAB, and CTKB

How does Pacific Biosciences of California compare to 10x Genomics?

Is TXG or PACB more profitable?

Which has more volatility and risk, TXG or PACB?

Which has preferable valuation and earnings, TXG or PACB?

Do analysts recommend TXG or PACB?

Do institutionals and insiders believe in TXG or PACB?

Does the media prefer TXG or PACB?

Summary

How does Pacific Biosciences of California compare to CryoPort?

Is PACB or CYRX more profitable?

Do analysts recommend PACB or CYRX?

Do institutionals & insiders hold more shares of PACB or CYRX?

Which has preferable earnings & valuation, PACB or CYRX?

Does the media refer more to PACB or CYRX?

Which has more volatility & risk, PACB or CYRX?

Summary

How does Pacific Biosciences of California compare to Evotec?

Which has stronger valuation & earnings, PACB or EVO?

Do institutionals and insiders hold more shares of PACB or EVO?

Do analysts recommend PACB or EVO?

Does the media refer more to PACB or EVO?

Is PACB or EVO more profitable?

Which has more risk and volatility, PACB or EVO?

Summary

How does Pacific Biosciences of California compare to Mesa Laboratories?

Which has preferable valuation & earnings, PACB or MLAB?

Is PACB or MLAB more profitable?

Do institutionals & insiders hold more shares of PACB or MLAB?

Do analysts prefer PACB or MLAB?

Which has more risk & volatility, PACB or MLAB?

Does the media favor PACB or MLAB?

Summary

How does Pacific Biosciences of California compare to Cytek Biosciences?

Do insiders & institutionals hold more shares of PACB or CTKB?

Is PACB or CTKB more profitable?

Do analysts rate PACB or CTKB?

Which has better valuation & earnings, PACB or CTKB?

Which has more volatility and risk, PACB or CTKB?

Does the media refer more to PACB or CTKB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB vs. The Competition

Pacific Biosciences of California Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools